Cite
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer.
MLA
Ding, Lin, et al. “Ropivacaine as a Novel AKT1 Specific Inhibitor Regulates the Stemness of Breast Cancer.” Journal of Experimental & Clinical Cancer Research (17569966), vol. 43, no. 1, Mar. 2023, pp. 1–18. EBSCOhost, https://doi.org/10.1186/s13046-024-03016-9.
APA
Ding, L., Jiang, H., Li, Q., Li, Q., Zhang, T.-T., Shang, L., Xie, B., Zhu, Y., Ding, K., Shi, X., Zhu, T., & Zhu, Y. (2023). Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer. Journal of Experimental & Clinical Cancer Research (17569966), 43(1), 1–18. https://doi.org/10.1186/s13046-024-03016-9
Chicago
Ding, Lin, Hui Jiang, Qiangwei Li, Qiushuang Li, Tian-Tian Zhang, Limeng Shang, Bin Xie, et al. 2023. “Ropivacaine as a Novel AKT1 Specific Inhibitor Regulates the Stemness of Breast Cancer.” Journal of Experimental & Clinical Cancer Research (17569966) 43 (1): 1–18. doi:10.1186/s13046-024-03016-9.